MAIA Biotechnology reaches enrollment milestones in lung cancer trials

MAIA Biotechnology said enrollment is complete in Part C of its Phase 2 THIO-101 study and that its Phase 3 THIO-104 trial has reached 65 patients enrolled. The company is developing ateganosine for non-small cell lung cancer.